Recombinant human gamma-interferon in primary hepatocellular carcinoma.
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
Forbes
A
A
Johnson
P J
PJ
Williams
R
R
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins; D007371:Interferon-gamma